Year All2024202320222021 KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October) 10-20-2021 KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market 10-19-2021 KemPharm to Present at the Benzinga Healthcare Small Cap Conference 09-27-2021 KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 09-23-2021 KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference 09-09-2021 KemPharm Appoints Tamara A. Seymour to Board of Directors 08-18-2021 KemPharm Reports Second Quarter 2021 Financial Results 08-12-2021 KemPharm to Report Second Quarter 2021 Results 08-05-2021 KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. 07-21-2021 KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement 06-18-2021
KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October) 10-20-2021
KemPharm to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference 09-09-2021
KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc. 07-21-2021
KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement 06-18-2021
